Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Despite CagriSema’s results ... amylin analogues such as petrelintide act through a different mechanism. By mimicking the hormone amylin, they suppress glucagon secretion, slow gastric emptying ...

I think you know, while the CagriSema of data left some with questions ... have two and perhaps more distinct characteristics in their putative mechanism of action. One is in contrast to GLP ...

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment ... on autoimmune disorders targeting the FcRn mechanism of action. A host of concerns weighed on ...

Novo Nordisk itself, meanwhile, recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – that will ...

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of ... in phase 3 known as CagriSema, which is based on semaglutide ...